MuSiC4Diabetes in Flanders: The Ghent Consortium Meeting Examined the project in All its Facets
On 14–15 October 2026, the MuSiC4Diabetes consortium met in Ghent for its third progress meeting, hosted by INDIGO in the heart of the old town. The two-day meeting brought together all project partners, members of the Scientific Advisory Board and our European Commission Project Officer, who joined virtually. It provided an important opportunity to review the progress made across the project.
System Interdependencies Need to Be Considered from the Very Beginning
After a warm welcome from coordinator Martin Richter (Fraunhofer EMFT) and Juan Ordonez (INDIGO), the meeting opened with an overview of the project. This was followed by a session on the work packages, during which partners shared updates on the development of the long-term, calibration-free multimetabolite sensor, the fully implantable insulin delivery system and the project’s data science activities. One key takeaway from the technical discussions was the need to account for the strong interdependencies between work packages and to maintain close coordination as the individual components move towards system integration and validation.
From Creation to Validation – Pathways to Deployment
The General Assembly meeting focused on governance and future priorities. Follow-up discussions covered a broad range of topics, including clinical, animal and in silico validation, as well as human factors, innovation management, communication, dissemination and exploitation. The consortium also discussed future activities within the EIC Pathfinder Healthcare Continuum Portfolio.
The second day focused in particular on the Exploitation Workshop, organised by members of Work Package 8. Partners identified ways to translate project results into future applications. The workshop encouraged them to develop a shared perspective on the project’s key exploitable results, stakeholder engagement and the steps needed to support the transition from research to potential uptake.
Identifying Priorities for the Next Phase of MuSiC4Diabetes
The meeting, and especially the open discussions among partners working on technical, clinical, management and exploitation activities, helped align expectations, address interfaces between activities and reinforce the shared ambition to deliver an integrated, impactful MuSiC4Diabetes system. With priorities for the coming period now more clearly defined, the partners will continue working towards their goal of creating an unobtrusive, continuous multi-metabolite monitoring device for diabetes care.
We would like to thank our partner INDIGO for the excellent organisation and warm hospitality in Ghent.


